Glaukos Corp.
$170.80
▲ +2.45%
+$4.08
NYSE · Healthcare · Medical Devices
· price updated 9h ago
GKOS · NYSE · Healthcare · Medical Devices · price updated 9h ago
$170.80
▲ +2.45% · +$4.08 today
AI research · $170.80
Operating record
Capital structure
Valuation
Forward P/E
Price against expected earnings
Needs attention · 1724% above Sector avg
1608.20x
Price / sales
Value assigned to each sales dollar
Rich · Above 8x annual sales
16.04x
Price / FCF
Price against free cash generation
No signal · Not enough data to judge
-
EV / EBITDA
Operating value including debt
No signal · Not enough data to judge
-
Quality
ROIC
Return earned on invested capital
Weak · Below 8% return on capital
-15.7%
ROE
Profit generated from shareholder equity
Needs attention · Among weakest in sector
-26.0%
Debt / equity
Balance-sheet leverage
Favorable · Exceptional vs sector peers
0.16x
Current ratio
Short-term assets against liabilities
Strong · Comfortable short-term liquidity
5.04x
Selected financial data sourced from StockAnalysis and refreshed weekly. Figures may be delayed and are for research context, not investment advice.
| company | mkt cap | P/E | rev growth | score |
|---|---|---|---|---|
| $9.83B | - | +41.5% | 49 | |
| $10.69B | 18.4 | +23.5% | 78 | |
| $4.88B | 20.3 | +10.3% | 77 | |
| $31.49B | 32.9 | +15.5% | 77 | |
| $1.08T | 41.4 | +47.4% | 76 |
US stock research
Glaukos Corp. tracked in the US core universe. GKOS was +2.5% in the latest available session at $170.80. Its reported market value was $9.83B with a trailing P/E of 0.0. Latest reported revenue was $612.84M, changing +41.5% year over year, with $-188.05M in net income.
Market snapshot updated Aug 3, 2026, 7:59 PM UTC.